Reading Time: 3 minutes “On the seventh day of Christmas MND research gives to you… our SEVEN research strategy themes” It’s New Year’s eve, a time to look back and celebrate on 2014 and our MND research achievements. It’s also a time to look to the future; in 2015 we will be funding new MND research in line with…
Reading Time: 3 minutes Saturday afternoon saw the 25th International Symposium on ALS/MND expand from two to three sessions running in parallel. Times have changed from the early years of the meeting when sessions finished at lunchtime on the second day because there wasn’t enough stuff to talk about! Rather than flitting between three different lecture halls, I opted to…
Reading Time: 4 minutes The 25th International Symposium on ALS/MND began today in Brussels, Belgium. More than 900 delegates joined the opening session to hear Dr Alfred Sandrock from Biogen Idec’s opening talk. The only proven drug for MND is riluzole. This is the only treatment to have passed all stages of clinical trial testing, showing it to be…
Reading Time: 3 minutes Dr Andrea Malaspina is an Association-funded researcher investigating biomarkers, or ‘biological fingerprints’ of MND. Here he blogs about working with patients and basic science. I regularly meet people living with MND due to my role as a Consultant Neurologist at the Bart’s and the London MND Care Centre and one of the most common questions…
Reading Time: 3 minutes Yesterday’s announcement by the biotechnology company Trophos SA of the lack of effectiveness of their compound olesoxime adds to the long list of drugs that have failed to live up to their early promise in the lab. It’s a story that’s common across the world of neurodegenerative disease, including common conditions such as Parkinson’s disease…
